World's Best Scientists 2026 revealed!

D-Index & Metrics

Microbiology

D-Index
74
Citations
22049
World Ranking
1564
National Ranking
132

Anton Pozniak publication distribution in Microbiology in 2026

The chart shows the distribution of publications by all Research.com ranked scientists in the field of Microbiology in 2026. The highlighted bar marks where Anton Pozniak sits on this spectrum.

55–64 publications: 8 scientists 65–74 publications: 29 scientists 75–84 publications: 55 scientists 85–94 publications: 112 scientists 95–104 publications: 137 scientists 105–114 publications: 190 scientists 115–124 publications: 235 scientists 125–134 publications: 234 scientists 135–144 publications: 288 scientists 145–154 publications: 264 scientists 155–164 publications: 264 scientists 165–174 publications: 253 scientists 175–184 publications: 276 scientists 185–194 publications: 190 scientists 195–204 publications: 233 scientists 205–214 publications: 207 scientists 215–224 publications: 198 scientists 225–234 publications: 155 scientists 235–244 publications: 161 scientists 245–254 publications: 160 scientists 255–264 publications: 146 scientists 265–274 publications: 139 scientists 275–284 publications: 148 scientists 285–294 publications: 115 scientists 295–304 publications: 96 scientists 305–314 publications: 88 scientists 315–324 publications: 106 scientists 325–334 publications: 65 scientists 335–344 publications: 76 scientists 345–354 publications: 64 scientists 355–364 publications: 62 scientists 365–374 publications: 65 scientists 375–384 publications: 61 scientists 385–394 publications: 34 scientists 395–404 publications: 44 scientists 405–414 publications: 36 scientists 415–424 publications: 35 scientists 425–434 publications: 29 scientists 435–444 publications: 33 scientists 445–454 publications: 34 scientists 455–464 publications: 25 scientists 465–474 publications: 26 scientists 475–484 publications: 20 scientists 485–494 publications: 19 scientists 495–504 publications: 16 scientists 505–514 publications: 17 scientists 515–524 publications: 23 scientists 525–534 publications: 14 scientists 535–544 publications: 14 scientists 545–554 publications: 18 scientists 555–564 publications: 12 scientists 565–574 publications: 7 scientists 575–584 publications: 9 scientists 585–594 publications: 9 scientists 595–604 publications: 9 scientists 605–614 publications: 7 scientists 615–624 publications: 9 scientists 625–634 publications: 7 scientists 635–644 publications: 4 scientists 645–654 publications: 5 scientists 655–664 publications: 6 scientists 665–674 publications: 7 scientists 675–678 publications: 3 scientists 679+ publications: 99 scientists
55 publications 679+

This scientist: 371 publications — 87th percentile

87% of scientists in this discipline score the same or lower.

The last bar groups every scientist with 679 publications or more.

Anton Pozniak D-index placement in Microbiology in 2026

The chart shows the D-index (discipline H-index) distribution of Microbiology scientists ranked by Research.com in 2026. The highlighted bar marks where Anton Pozniak sits on this spectrum.

40 D-Index: 30 scientists 41 D-Index: 86 scientists 42 D-Index: 90 scientists 43 D-Index: 117 scientists 44 D-Index: 122 scientists 45 D-Index: 123 scientists 46 D-Index: 108 scientists 47 D-Index: 110 scientists 48 D-Index: 106 scientists 49 D-Index: 109 scientists 50 D-Index: 129 scientists 51 D-Index: 111 scientists 52 D-Index: 116 scientists 53 D-Index: 127 scientists 54 D-Index: 134 scientists 55 D-Index: 134 scientists 56 D-Index: 111 scientists 57 D-Index: 136 scientists 58 D-Index: 162 scientists 59 D-Index: 151 scientists 60 D-Index: 139 scientists 61 D-Index: 122 scientists 62 D-Index: 126 scientists 63 D-Index: 144 scientists 64 D-Index: 109 scientists 65 D-Index: 103 scientists 66 D-Index: 124 scientists 67 D-Index: 112 scientists 68 D-Index: 103 scientists 69 D-Index: 131 scientists 70 D-Index: 93 scientists 71 D-Index: 93 scientists 72 D-Index: 96 scientists 73 D-Index: 92 scientists 74 D-Index: 80 scientists 75 D-Index: 66 scientists 76 D-Index: 87 scientists 77 D-Index: 60 scientists 78 D-Index: 73 scientists 79 D-Index: 59 scientists 80 D-Index: 57 scientists 81 D-Index: 55 scientists 82 D-Index: 47 scientists 83 D-Index: 77 scientists 84 D-Index: 50 scientists 85 D-Index: 45 scientists 86 D-Index: 42 scientists 87 D-Index: 41 scientists 88 D-Index: 32 scientists 89 D-Index: 38 scientists 90 D-Index: 35 scientists 91 D-Index: 34 scientists 92 D-Index: 27 scientists 93 D-Index: 26 scientists 94 D-Index: 33 scientists 95 D-Index: 22 scientists 96 D-Index: 37 scientists 97 D-Index: 22 scientists 98 D-Index: 21 scientists 99 D-Index: 22 scientists 100 D-Index: 30 scientists 101 D-Index: 16 scientists 102 D-Index: 20 scientists 103 D-Index: 17 scientists 104 D-Index: 19 scientists 105 D-Index: 16 scientists 106 D-Index: 19 scientists 107 D-Index: 18 scientists 108 D-Index: 14 scientists 109 D-Index: 10 scientists 110 D-Index: 9 scientists 111 D-Index: 7 scientists 112 D-Index: 11 scientists 113 D-Index: 6 scientists 114 D-Index: 15 scientists 115 D-Index: 10 scientists 116 D-Index: 12 scientists 117 D-Index: 7 scientists 118 D-Index: 10 scientists 119 D-Index: 10 scientists 120 D-Index: 11 scientists 121 D-Index: 2 scientists 122 D-Index: 7 scientists 123 D-Index: 12 scientists 124 D-Index: 5 scientists 125 D-Index: 9 scientists 126 D-Index: 6 scientists 127+ D-Index: 95 scientists
40 D-Index 127+

This scientist: 74 D-Index — 72nd percentile

72% of scientists in this discipline score the same or lower.

The last bar groups every scientist with 127 D-Index or more.

Overview

Anton Pozniak is affiliated with the London School of Hygiene & Tropical Medicine in the United Kingdom, with a research focus primarily in the field of Medicine.

Their work centers around infectious diseases, emergency medicine, virology, epidemiology, and surgery. The core themes of their research involve HIV/AIDS, with particular emphasis on HIV/AIDS research and interventions, drug development and treatment for HIV, HIV-related health complications and treatments, and the intersection of HIV with drug use and sexual risk. Additional topics include Pneumocystis jirovecii pneumonia detection and treatment, as well as clinical research related to COVID-19.

Anton Pozniak has published extensively in several scientific journals. The most frequent publication venues include:

  • The Lancet HIV
  • AIDS
  • Journal of Antimicrobial Chemotherapy
  • HIV Medicine
  • Clinical Infectious Diseases

The following are selected recent papers authored or coauthored by Anton Pozniak, showcasing the range and focus of their research:

  • Recommendations for the Management of Drug-Drug Interactions Between the COVID-19 Antiviral Nirmatrelvir/Ritonavir (Paxlovid) and Comedications, 2022, Clinical Pharmacology & Therapeutics
  • Consensus statement on the role of health systems in advancing the long-term well-being of people living with HIV, 2021, Nature Communications
  • Cognitive impairment in people living with HIV: consensus recommendations for a new approach, 2023, Nature Reviews Neurology
  • Epigenetic age acceleration changes 2 years after antiretroviral therapy initiation in adults with HIV: a substudy of the NEAT001/ANRS143 randomised trial, 2021, The Lancet HIV
  • BHIVA guidelines on antiretroviral treatment for adults living with HIV-1 2022, 2022, HIV Medicine

Frequent collaborators include several researchers with whom Anton Pozniak has coauthored multiple publications. These coauthors include:

  • Christoph Stephan, with 22 joint publications
  • Marta Boffito, with 14 joint publications
  • Giovanni Guaraldi, with 12 joint publications
  • Mar Masiá, with 12 joint publications
  • Laura Waters, with 11 joint publications

Best Publications

  • Efficacy and safety of tenofovir DF vs stavudine in combination therapy in antiretroviral-naive patients: a 3-year randomized trial.

    Joel E. Gallant;Schlomo Staszewski;Anton L. Pozniak;Edwin DeJesus

  • Tenofovir DF, Emtricitabine, and Efavirenz vs. Zidovudine, Lamivudine, and Efavirenz for HIV

    Joel E. Gallant;Edwin Dejesus;José R. Arribas;Anton L. Pozniak

  • British HIV Association guidelines for the treatment of HIV-1-infected adults with antiretroviral therapy 2008

    B G Gazzard;Jane Anderson;Abdel Babiker;Marta Boffito

  • Human Immunodeficiency Virus Type 1 Elite Neutralizers: Individuals with Broad and Potent Neutralizing Activity Identified by Using a High-Throughput Neutralization Assay together with an Analytical Selection Algorithm

    Melissa D. Simek;Wasima Rida;Frances H. Priddy;Pham Pung

  • Tenofovir alafenamide versus tenofovir disoproxil fumarate, coformulated with elvitegravir, cobicistat, and emtricitabine, for initial treatment of HIV-1 infection: two randomised, double-blind, phase 3, non-inferiority trials

    Paul E Sax;David Wohl;Michael T Yin;Frank Post

  • Efficacy of short-term monotherapy with maraviroc, a new CCR5 antagonist, in patients infected with HIV-1.

    Gerd Fätkenheuer;Anton L Pozniak;Margaret A Johnson;Andreas Plettenberg

  • Loss of blood CD11c+ myeloid and CD11c−plasmacytoid dendritic cells in patients with HIV-1 infection correlates with HIV-1 RNA virus load

    Heather Donaghy;Anton Pozniak;Brian Gazzard;Nad Qazi

  • Treatment of tuberculosis in HIV-infected persons in the era of highly active antiretroviral therapy.

    Gillian L. Dean;Simon G. Edwards;Natalie J. Ives;Gail Matthews

  • Advancing global health and strengthening the HIV response in the era of the Sustainable Development Goals: the International AIDS Society-Lancet Commission

    Linda Gail Bekker;Linda Gail Bekker;George Alleyne;Stefan Baral;Javier Cepeda

  • Episodic Sexual Transmission of HIV Revealed by Molecular Phylodynamics

    Fraser Lewis;Gareth J Hughes;Andrew Rambaut;Anton Pozniak

  • European AIDS Clinical Society (EACS) guidelines for the clinical management and treatment of HIV-infected adults

    N Clumeck;A Pozniak;F Raffi

  • Emergence of CXCR4-Using Human Immunodeficiency Virus Type 1 (HIV-1) Variants in a Minority of HIV-1-Infected Patients following Treatment with the CCR5 Antagonist Maraviroc Is from a Pretreatment CXCR4-Using Virus Reservoir

    Mike Westby;Marilyn Lewis;Jeannette Whitcomb;Mike Youle

  • Effect of transmitted drug resistance on virological and immunological response to initial combination antiretroviral therapy for HIV (EuroCoord-CHAIN joint project): a European multicohort study

    Linda Wittkop;Huldrych F Günthard;Frank de Wolf;David Dunn

  • British HIV Association guidelines for the treatment of HIV-1-positive adults with antiretroviral therapy 2012

    Ian Williams;Duncan Churchill;Jane Anderson;Marta Boffito

  • Dolutegravir versus raltegravir in antiretroviral-experienced, integrase-inhibitor-naive adults with HIV: week 48 results from the randomised, double-blind, non-inferiority SAILING study.

    Pedro Cahn;Anton L Pozniak;Horacio Mingrone;Andrey Shuldyakov

  • Coformulated bictegravir, emtricitabine, and tenofovir alafenamide versus dolutegravir with emtricitabine and tenofovir alafenamide, for initial treatment of HIV-1 infection (GS-US-380–1490): a randomised, double-blind, multicentre, phase 3, non-inferiority trial

    Paul E. Sax;Anton Pozniak;M. Luisa Montes;Ellen Koenig

  • Can the UNAIDS 90-90-90 target be achieved? A systematic analysis of national HIV treatment cascades.

    Jacob Levi;Alice Raymond;Anton Pozniak;Pietro Vernazza

  • Efficacy of Tenofovir Disoproxil Fumarate in Antiretroviral Therapy-Naive and -Experienced Patients Coinfected with HIV-1 and Hepatitis B Virus

    Gregory J. Dore;David A. Cooper;Anton L. Pozniak;Edwin DeJesus

  • Tenofovir disoproxil fumarate, emtricitabine, and efavirenz compared with zidovudine/lamivudine and efavirenz in treatment-naive patients: 144-week analysis.

    Jose R. Arribas;Anton L. Pozniak;Joel E. Gallant;Edwin DeJesus

  • Tenofovir disoproxil fumarate, emtricitabine, and efavirenz versus fixed-dose zidovudine/lamivudine and efavirenz in antiretroviral-naive patients: virologic, immunologic, and morphologic changes--a 96-week analysis.

    Anton L. Pozniak;Joel E. Gallant;Joel E. Gallant;Edwin DeJesus;Jose R. Arribas;Jose R. Arribas

  • British HIV Association guidelines for the treatment of HIV-1-positive adults with antiretroviral therapy 2012 (Updated November 2013. All changed text is cast in yellow highlight.).

    Ian Williams;Ian Williams;Duncan Churchill;Jane Anderson;Marta Boffito

  • Tenofovir disoproxil fumarate in nucleoside-resistant HIV-1 infection: a randomized trial.

    Kathleen Squires;Anton L. Pozniak;Gerald Pierone;Corklin R. Steinhart

  • Switching to Tenofovir Alafenamide, Coformulated With Elvitegravir, Cobicistat, and Emtricitabine, in HIV-Infected Patients With Renal Impairment: 48-Week Results From a Single-Arm, Multicenter, Open-Label Phase 3 Study

    Anton Pozniak;Jose R. Arribas;Joseph Gathe;Samir K. Gupta

  • Efficacy and safety of TMC114/ritonavir in treatment-experienced HIV patients: 24-week results of POWER 1.

    Christine Katlama;Roberto Esposito;Jose M Gatell;Jean-Christophe Goffard

Frequent Co-Authors

Marta Boffito
Marta Boffito Imperial College London
Brian Gazzard
Brian Gazzard St Bartholomew's Hospital
Mark Nelson
Mark Nelson University of Vermont
David Back
David Back University of Liverpool
Graeme Moyle
Graeme Moyle Chelsea and Westminster Hospital NHS Foundation Trust
Andrew Hill
Andrew Hill University of Liverpool
Saye Khoo
Saye Khoo University of Liverpool
David Dunn
David Dunn University College London
Alan Winston
Alan Winston Imperial College London
Deenan Pillay
Deenan Pillay University College London

If you think any of the details on this page are incorrect, let us know.

Report an issue

We appreciate your kind effort to assist us to improve this page, it would be helpful providing us with as much detail as possible in the text box below:

Related Online Degrees & Career Pathways

For those interested in microbiology, exploring related online degrees can broaden career opportunities. Many students complement their studies with programs that focus on healthcare administration or public health. For example, pursuing an online medical billing and coding certificate fast can provide a quick pathway into the administrative side of healthcare, which is closely related to laboratory work and medical data management.

Additionally, if you are considering expanding your expertise in health sciences, there are many online medical programs available that offer flexible learning options. These programs often include courses that align with microbiology, such as immunology and infectious diseases.

For those looking to make an impact on community health, enrolling in some of the online mph programs easy to get into can be a strategic choice. Public health degrees incorporate microbiology principles to address disease prevention and health promotion on a larger scale.

Moreover, careers like becoming a certified child life specialist integrate knowledge of healthcare environments, which microbiologists may support. Researching the certified child life specialist salary and career requirements can help guide professionals interested in multidisciplinary healthcare sectors.

Best Scientists Citing Anton Pozniak

Trending Scientists

Recently Published Articles